{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Siegel PM"],"funding":["Deutsche Forschungsgemeinschaft","Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.","European Research Council","Deutsche Stiftung für Herzforschung","National Health and Medical Research Council","Leukemia Foundation"],"pagination":["17"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7960600"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["116(1)"],"pubmed_abstract":["The monocyte β<sub>2</sub>-integrin Mac-1 is crucial for leukocyte-endothelium interaction, rendering it an attractive therapeutic target for acute and chronic inflammation. Using phage display, a Designed-Ankyrin-Repeat-Protein (DARPin) was selected as a novel binding protein targeting and blocking the α<sub>M</sub> I-domain, an activation-specific epitope of Mac-1. This DARPin, named F7, specifically binds to activated Mac-1 on mouse and human monocytes as determined by flow cytometry. Homology modelling and docking studies defined distinct interaction sites which were verified by mutagenesis. Intravital microscopy showed reduced leukocyte-endothelium adhesion in mice treated with this DARPin. Using mouse models of sepsis, myocarditis and ischaemia/reperfusion injury, we demonstrate ther"],"journal":["Basic research in cardiology"],"pubmed_title":["A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction."],"pmcid":["PMC7960600"],"funding_grant_id":["853425","1174098"],"pubmed_authors":["Anto-Michel N","Diehl P","Hollederer L","Peter K","Waggershauser P","Helbing T","Wolf D","Mitre LS","Przewosnik A","Flierl U","Siegel PM","Mauler M","Wang X","Holien J","Stankova I","Orlean L","Tonnar X","Lamprecht C","Vedecnik C","Moser M","Parker MW","Bender I","Bojti I","Bassler N","Ehrlich J","Li T","Bode C"],"additional_accession":[]},"is_claimable":false,"name":"A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction.","description":"The monocyte β<sub>2</sub>-integrin Mac-1 is crucial for leukocyte-endothelium interaction, rendering it an attractive therapeutic target for acute and chronic inflammation. Using phage display, a Designed-Ankyrin-Repeat-Protein (DARPin) was selected as a novel binding protein targeting and blocking the α<sub>M</sub> I-domain, an activation-specific epitope of Mac-1. This DARPin, named F7, specifically binds to activated Mac-1 on mouse and human monocytes as determined by flow cytometry. Homology modelling and docking studies defined distinct interaction sites which were verified by mutagenesis. Intravital microscopy showed reduced leukocyte-endothelium adhesion in mice treated with this DARPin. Using mouse models of sepsis, myocarditis and ischaemia/reperfusion injury, we demonstrate ther","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2025-04-04T12:53:10.93Z","creation":"2022-02-09T08:01:43.811Z"},"accession":"S-EPMC7960600","cross_references":{"pubmed":["33721106"],"doi":["10.1007/s00395-021-00849-9"]}}